Developing new immune system boosters for tuberculosis treatment
Synthetic Macrophage-inducible C-type lectin (Mincle) Agonists: Screening, Design, and Formulation in combination Th17 adjuvants
['FUNDING_OTHER'] · VACCINE FORMULATION INSTITUTE (CH) LTD · NIH-11202983
This study is exploring new ways to boost the immune system's fight against tuberculosis by testing special compounds that help vaccines work better, and it's aimed at finding treatments that could eventually help people with this condition.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VACCINE FORMULATION INSTITUTE (CH) LTD (nih funded) |
| Locations | 1 site (PLAN-LES-OUATES, SWITZERLAND) |
| Trial ID | NIH-11202983 on ClinicalTrials.gov |
What this research studies
This research focuses on creating and testing new chemical compounds that activate a specific part of the immune system, known as Mincle agonists, to enhance the body's response against tuberculosis. By combining these compounds with various carriers and other immune stimulants, the researchers aim to identify effective adjuvants that can improve vaccine efficacy. The effectiveness of these lead adjuvants will be evaluated using animal models that mimic tuberculosis infection, providing insights into their potential use in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of tuberculosis or those who may benefit from enhanced vaccination strategies.
Not a fit: Patients who are not at risk for tuberculosis or those who have already been effectively treated may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines and treatments for tuberculosis, improving patient outcomes.
How similar studies have performed: While the approach of using Mincle agonists is innovative, similar strategies in immunology have shown promise in enhancing vaccine responses, suggesting potential for success.
Where this research is happening
PLAN-LES-OUATES, SWITZERLAND
- VACCINE FORMULATION INSTITUTE (CH) LTD — PLAN-LES-OUATES, SWITZERLAND (ACTIVE)
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.